In contrast with the IGF1R antagonist monoclonal antibodies and IGF1R tyrosine kinase inhibitors, these compounds do not cause hyperglycemia, as they do not compromise insulin action [23,24]. This evidence concerns the gene IGF1R and Hyperglycemia.